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Resumo
Os autores apresentam um caso de carcinoma 
neuroendócrino de pequenas células da bexiga 
(SmCC) numa mulher de 60 anos de idade 
que se apresentou no serviço de Urgência 
com hematúria macroscópica e desconforto 
pélvico. A tomografia computadorizada revelou 
um tumor polipóide de base larga na parede 
posterior da bexiga infiltrando ambos os ureteres 
e condicionando hidronefrose bilateral. Após 
tentativa de ressecção transuretral a anatomia 
patológica mostrou um tumor maligno, não 
urotelial, e a doente foi encaminhada para o 
nosso centro. A ressonância magnética realizada 
para melhor caracterização e estadiamento local, 
mostrou um tumor agressivo com invasão da 
gordura perivesical. O SmCC é um tipo raro 
de tumor da bexiga com apresentação clínica 
e macroscópica semelhantes ao carcinoma 
urotelial. Radiologicamente é geralmente um 
tumor agressivo, com doença avançada no 
diagnóstico inicial. As características clínicas e 
radiológicas do SmCC da bexiga são revistas, 
incluindo uma discussão sobre a utilidade dos 
marcadores imunohistoquímicos.
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Abstract
The authors describe a case of  small cell 
neuroendocrine carcinoma (SmCC) of  the 
urinary bladder in a 60-year-old woman 
who arrived at the Emergency Room with 
macroscopic hematuria and pelvic discomfort. 
Computed tomography revealed a broad-
based polypoid tumor on the posterior wall 
of  the bladder, infiltrating both ureters with 
bilateral hydronephrosis. After an attempt of  
transurethral resection, the pathology revealed a 
malignant, non-urothelial tumor, and the patient 
was referred to our center. Magnetic resonance 
imaging performed for better characterization 
and local staging, confirmed an aggressive tumor 
with perivesical fat invasion. SmCC is a rare type 
of  bladder tumor with clinical and macroscopic 
presentation similar to urothelial carcinoma. 
Radiologically it is usually an aggressive tumor, 
with advanced disease at the initial diagnosis. 
The clinical and radiological features of  bladder 
SmCC are revised, including a discussion on the 
usefulness of  immunohistochemical markers. 
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Radiological Case Report / Caso Clínico
Case Presentation
A 60-year-old woman with gross hematuria and pelvic 
discomfort was admitted in the emergency department of  
a tertiary hospital. She was a sporadic smoker with no other 
relevant personal and familial histories. On physical examination, 
a painless mass was detected in hypogastric region.  Routine 
laboratory data confirmed low hemoglobin level (8.6 g/dL). 
Pelvic ultrasonography (US) and abdominopelvic computed 
tomography (CT) revealed a polypoid tumor with irregular 
margins in the posterior urinary bladder wall measuring about 
10cm and infiltrating both ureters with bilateral hydronephrosis. 
Cystoscopy was performed, and transurethral resection of  the 
tumor was attempted without success. The artifacts of  the 
sampled tumor tissue were initially misleading, and the first 
pathology analysis suggested the diagnosis of  myxoid/round-
cell liposarcoma.
Positron emission tomography–computed tomography (PET-
CT) was therefore performed and no metastatic disease was 
identified.  The patient was referred to our institute and 
pelvic magnetic resonance (MR) imaging was performed for 
further characterization and tumor staging. MRI revealed a 
large broad-based polypoid tumor with lobulated margins 
in the posterior bladder wall. The tumor invaded the bladder 
wall with extension to the perivesical fat without invasion 
of  the vagina or uterus (Figure 1). On diffusion-weighted 
imaging (DWI), the tumor showed diffused restriction, 
with high signal intensity on b 1000 and low signal on 
ADC map (Figures 2 a-b). On dynamic contrast-enhanced 
T1-weighted MR imaging the tumor demonstrated early 
and intense enhancement (Figure 2c). No lymph node 
metastases or other pelvic metastases were identified.
Pelvic exenteration was performed. The urinary bladder 
measured 100 x 70 x 50mm and contained a white firm 
tumor involving the trigonus and the base. The tumor 
measured about 6cm in greatest dimension and was about 
70% necrotic. The tumor invaded the perivesical fat but 
not the uterus or the adnexa. Microscopy revealed a small 
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cell neuroendocrine carcinoma with a minor component 
of  invasive urothelial carcinoma (< 5%) (Figure 3a). 
The tumor cells expressed chromogranin A (Figure 3b), 
synaptophysin, thyroid transcription factor 1 (TTF-1), 
uroplakin, and focally S100. CD99 was negative.
Fig. 1 – Pelvic MR imaging in a 
60-year-old woman with Small 
Cell Carcinoma of  the urinary 
bladder. Axial (a) and sagittal 
(b) high-resolution T2-weighted 
images showed a polypoid 
broad-based solitary tumor 
(asterixis) on the posterior wall 
of  the bladder with bilateral 
ureter invasion (arrows) and 
mural invasion with perivesical 
fat infiltration (open arrow). No 
lymph node metastases nor 
other lesions were identified.
Eight weeks after surgery, another PET-CT was performed 
and revealed multifocal liver metastases and supraclavicular, 
retroperitoneal and bilateral iliac lymph node metastases. 
Chemotherapy with carboplatin and etoposide was started.
Fig. 2 – Pelvic MR imaging in a 60-year-old woman with Small Cell Carcinoma of  the urinary bladder. Diffusion-weighted imaging confirmed a high 
cellular tumor with high signal intensity on b 1000sec/mm2 (a) and corresponding low signal on ADC map (b). On dynamic contrast enhanced MR 
imaging  (c), the tumor demonstrated rapid and intense enhancement.
Fig. 3 – Photomicrograph (original magnification, ×100; hematoxylin-eosin stain) (a) showed sheets of  hyperchromatic cells with 
scant cytoplasm, nuclear molding and inconspicuous nucleoli. Immunohistochemical stain showed positivity for chromogranin A (b).
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Discussion
Neuroendocrine tumors (NETs) represent a diverse group 
of  rare neoplasms arising from cells of  the neuroendocrine 
system.1 Although NETs most commonly originate in the 
gastrointestinal tract, they may originate anywhere in the 
body due to the wide distribution of  the neuroendocrine 
system.2 NETs of  the urinary bladder comprise <1 % of  
all urinary bladder malignancies. According to the 2016 
World Health Organization Classification of  Urinary 
System and Male Genital Organ Classification system, 
NETs of  the urinary bladder can be separated in four 
subtypes with crescent aggressiveness:  well-differentiated 
neuroendocrine neoplasms (carcinoids), paragangliomas, 
large cell carcinoma, and small cell carcinoma (SmCC).3
SmCC of  the urinary bladder is extremely rare with an 
estimated rate of  0.14 cases per 100000 people. SmCC 
predominantly affects patients in the 6th to 7th decades of  
life with a relative male preponderance from 2:1 to 5:1.4,5 
Hematuria with void symptoms is the most common 
clinical presentation. Rarely paraneoplastic syndromes 
can be present.3 SmCC is highly aggressive with advanced 
disease common at the time of  presentation. About 60% 
of  patients present with metastatic disease at time of  
diagnosis and muscle invasive disease has been reported in 
about 95% of  cases at surgery. Prognosis is therefore poor, 
with 5-year survival rates ranging from 8 to 40%.6,7
On imaging, CT urography has a sensitivity and specificity 
of  over 90% for the diagnosis of  bladder cancer in patients 
with hematuria. However, CT urography cannot be used as 
a replacement for diagnostic cystoscopy in most patients 
with suspected bladder cancer, particularly because of  its 
low confidence in cases with flat lesions and lesions at the 
bladder base adjacent to a hypertrophic prostate gland. Due 
to its high soft-tissue contrast resolution, MR imaging has 
shown a more accurate staging of  bladder carcinoma than 
CT, with the advantage of  involving no ionizing resolution. 
MR imaging allows better differentiation of  bladder 
wall layers and therefore it depicts better the intramural 
invasion as well as extravesical extension. The multiplanar 
capability of  MR imaging allows image acquisition in 
different planes to minimize partial volume averaging and 
optimize imaging when evaluating the depth of  bladder 
wall invasion. Moreover, the advances of  functional 
sequences, particularly diffusion-weighted imaging (DWI) 
and dynamic contrast enhanced (DCE) MR imaging, have 
made multiparametric MR imaging feasible for the local 
staging of  bladder cancer.8
Although SmCC remains difficult to distinguish on imaging 
from more common urothelial neoplasms such as urothelial 
carcinoma (UC), there are some features that reveal this 
diagnosis. SmCC tends to present itself  as an aggressive 
solitary large bladder mass with a variable amount of  
necrosis, calcification, and enhancement. Unlike classic UC 
of  the bladder that usually shows as a superficial neoplasm 
with focal asymmetric bladder wall thickening, SmCC tends 
to present itself  as a polypoid intramural mass with a broad 
base and extension to the perivesical fat, with or without 
invasion of  surrounding organs (such as seminal vesicles, 
ureters or vagina). Systemic disease with lymph node or 
liver metastases is common at the time of  diagnosis or 
early in the course of  disease.9,10 Synchronous bladder or 
upper urinary tract lesions are uncommon and may help 
to differentiate SmCC from classic UC. Moreover, the 
presence of  a large intraluminal bladder mass is seen in 
less than 20% of  urothelial carcinomas and should raise 
suspicion for another form of  bladder cancer, such as 
neuroendocrine carcinoma, squamous cell carcinoma 
adenocarcinoma or rhabdomyosarcoma.5,11
On pathology grounds, the diagnosis of  bladder 
SmCC is based on morphology combined with 
immunohistochemistry to document neuroendocrine 
differentiation. On microscopic examination, SmCC 
consists of  diffuse sheets or nests of  small or intermediate 
fusiform cells with nuclear molding, scant cytoplasm, 
inconspicuous nucleoli, and evenly dispersed “salt-and-
pepper chromatin”. Frequent mitoses, crush artifact and 
geographic necrosis are indicative of  its high proliferation 
rate. Vascular invasion is commonly present. Urinary 
bladder SmCC is frequently admixed with another histologic 
subtypes, most commonly conventional UC, including 
carcinoma in situ, followed by squamous cell carcinoma and 
adenocarcinoma and, rarely, even sarcomatoid carcinoma.12
Immunohistochemistry usually shows tumor positivity for 
neuroendocrine markers chromogranin A, synaptophysin, 
neuron-specific enolase, and CD56, and, less frequently, for 
TTF-1. Cytokeratins CAM 5.2 and CK7 are usually positive, 
whereas CK20 is negative (by contrast, this is positive in 
Merkel cell carcinoma and in about 40-70% of  UC). Cell-
cycle protein p16 is positive in up to 95% of  SmCC and 
squamous-cell markers p63 and p40 are almost always 
negative. Therefore, the typical immunohistochemical 
profile of  bladder SmCC is p16+, p63-, and CK20-, 
while high-grade UC’s is usually p16-, p63+, and CK20+. 
Distinction between SmCC and lymphoma is made by 
a negative CD45 and positive neuroendocrine profile. 
Distinction with prostate origin of  SmCC may be 
challenging but can be achieved by a negative prostate 
specific antigen (PSA) and a low staining rate of  p501S.3,12
Because of  the rarity of  the disease and paucity of  clinical 
studies there is no standard therapy for primary SmCC 
of  the urinary bladder and multimodality treatment is 
often employed.13,14 Survival mainly depends on the stage 
at presentation. Clinicopathological parameters such as 
age, gender, and the presence of  nonsmall cell carcinoma 
components do not appear to impact on outcomes.3  Options 
for treatment of  limited disease include transurethral 
resection, radical cystectomy, and radiation. Simple 
transurethral resection may result in high recurrence rates 
and poor survival periods of  3-6 months, but some studies 
also reported no difference in the survival rates between 
patients who underwent radical cystectomy and those who 
did not.13 Multimodal therapies using a combination of  
neoadjuvant (platinum-based) chemotherapy and radical 
cystectomy or radiation therapy may improve long-term 
survival. Other approaches combine partial cystectomy or 
radical cystectomy with adjuvant chemotherapy. In patients 
presenting extensive disease, chemotherapy (with cisplatin, 
gemcitabine, and paclitaxel) as first-line agents, combined 
or not with cystectomy, is the mainstay of  treatment and 
extends the overall survival from 8 to 15 months. Despite 
chemotherapy and local treatment, distant metastases occur 
early within the first 6 months after presentation.14
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